168 related articles for article (PubMed ID: 26318843)
1. [Review of the current use of rituximab during 4 years in a French university hospital].
Reynaud Q; Killian M; Robles A; Mounsef F; Camdessanché JP; Mariat C; Cathébras P
Rev Med Interne; 2015 Dec; 36(12):800-12. PubMed ID: 26318843
[TBL] [Abstract][Full Text] [Related]
2. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
4. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
6. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
8. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Rituximab in Connective Tissue Disease related Interstitial Lung Disease.
Fitzgerald DB; Moloney F; Twomey M; O'Connell JO; Cronin O; Harty L; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):215-21. PubMed ID: 26422566
[TBL] [Abstract][Full Text] [Related]
10. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
11. Experience with low-dose rituximab in off-label indications at two tertiary hospitals.
Chay J; Donovan P; Cummins L; Kubler P; Pillans P
Intern Med J; 2013 Aug; 43(8):871-82. PubMed ID: 23919335
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.
Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M
Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716
[TBL] [Abstract][Full Text] [Related]
13. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
Cho HH; Jin SP; Chung JH
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
[TBL] [Abstract][Full Text] [Related]
14. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of rituximab in autoimmune blistering diseases.
Ahmed AR; Shetty S
Am J Clin Dermatol; 2015 Jun; 16(3):167-77. PubMed ID: 25791770
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
Ebbo M; Grados A; Samson M; Groh M; Loundou A; Rigolet A; Terrier B; Guillaud C; Carra-Dallière C; Renou F; Pozdzik A; Labauge P; Palat S; Berthelot JM; Pennaforte JL; Wynckel A; Lebas C; Le Gouellec N; Quémeneur T; Dahan K; Carbonnel F; Leroux G; Perlat A; Mathian A; Cacoub P; Hachulla E; Costedoat-Chalumeau N; Harlé JR; Schleinitz N
PLoS One; 2017; 12(9):e0183844. PubMed ID: 28915275
[TBL] [Abstract][Full Text] [Related]
17. [Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases].
Catroux M; Lauda-Maillen M; Pathe M; De Boisgrollier de Ruolz AC; Cazenave-Roblot F; Roblot P; Souchaud-Debouverie O
Rev Med Interne; 2017 Mar; 38(3):160-166. PubMed ID: 27836224
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort.
Lee WJ; Lee ST; Byun JI; Sunwoo JS; Kim TJ; Lim JA; Moon J; Lee HS; Shin YW; Lee KJ; Kim S; Jung KH; Jung KY; Chu K; Lee SK
Neurology; 2016 May; 86(18):1683-91. PubMed ID: 27037228
[TBL] [Abstract][Full Text] [Related]
19. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
20. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.
Quartuccio L; Zuliani F; Corazza L; Scaini P; Zani R; Lenzi M; Tavoni A; Sebastiani M; Baldovino S; Urraro T; Saccardo F; Sbreglia C; Mazzaro C; Pioltelli P; Fraticelli P; Filippini D; Gabrielli A; Perrella O; Scarpato S; Roccatello D; Zignego AL; Ferri C; Bombardieri S; Pietrogrande M; Monti G; Galli M; De Vita S
J Autoimmun; 2015 Sep; 63():88-93. PubMed ID: 26255249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]